Literature DB >> 1826593

In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile.

F Biavasco1, E Manso, P E Varaldo.   

Abstract

Seventy strains of Clostridium difficile, all isolated from symptomatic patients, were found to be uniformly susceptible to ramoplanin, a new glycolipodepsipeptide antibiotic, and to four glycopeptides (vancomycin, teicoplanin, and two semisynthetic teicoplanin derivatives). Ramoplanin is recommended for further evaluation in the treatment of C. difficile-associated disease.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1826593      PMCID： PMC244968          DOI： 10.1128/AAC.35.1.195

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Enterococcal resistance to vancomycin and related cyclic glycopeptide antibiotics.

Authors:  D M Shlaes; B Binczewski
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-02       Impact factor: 3.267

2.  In vitro activity of A-16686, a new glycopeptide.

Authors:  H C Neu; N M Neu
Journal:  Chemotherapy       Date:  1986       Impact factor: 2.544

3.  Treatment of Clostridium difficile colitis.

Authors:  J G Bartlett
Journal:  Gastroenterology       Date:  1985-11       Impact factor: 22.682

Review 4.  Clostridium difficile: clinical considerations.

Authors:  J G Bartlett
Journal:  Rev Infect Dis       Date:  1990 Jan-Feb

5.  A-16686, a new antibiotic from Actinoplanes. II. Biological properties.

Authors:  R Pallanza; M Berti; R Scotti; E Randisi; V Arioli
Journal:  J Antibiot (Tokyo)       Date:  1984-04       Impact factor: 2.649

6.  Ramoplanin (A-16686), a new glycolipodepsipeptide antibiotic. III. Structure elucidation.

Authors:  R Ciabatti; J K Kettenring; G Winters; G Tuan; L Zerilli; B Cavalleri
Journal:  J Antibiot (Tokyo)       Date:  1989-02       Impact factor: 2.649

7.  Some chemical and physical characteristics of pantomycin, and antiobiotic isolated from Streptomyces hygroscopicus.

Authors:  S Gurusiddaiah; S O Graham
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

8.  Inhibition of peptidoglycan biosynthesis by ramoplanin.

Authors:  E A Somner; P E Reynolds
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

9.  A-16686, a new antibiotic from Actinoplanes. I. Fermentation, isolation and preliminary physico-chemical characteristics.

Authors:  B Cavalleri; H Pagani; G Volpe; E Selva; F Parenti
Journal:  J Antibiot (Tokyo)       Date:  1984-04       Impact factor: 2.649

10.  In vitro activity of teichomycin and vancomycin alone and in combination with rifampin.

Authors:  P E Varaldo; E Debbia; G C Schito
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191
View more
  16 in total

Review 1.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  In vitro activities of three semisynthetic amide derivatives of teicoplanin, MDL 62208, MDL 62211, and MDL 62873.

Authors:  F Biavasco; R Lupidi; P E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

Review 3.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

4.  In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole.

Authors:  T Peláez; L Alcalá; R Alonso; A Martín-López; V García-Arias; M Marín; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

5.  Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997.

Authors:  F Barbut; D Decré; B Burghoffer; D Lesage; F Delisle; V Lalande; M Delmée; V Avesani; N Sano; C Coudert; J C Petit
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

6.  Antimicrobial susceptibilities of enterococci isolated from hospitalized patients.

Authors:  M Venditti; A Tarasi; V Gelfusa; E Nicastri; A Penni; P Martino
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

7.  Generation of ramoplanin-resistant Staphylococcus aureus.

Authors:  John W Schmidt; Adrienne Greenough; Michelle Burns; Andrea E Luteran; Dewey G McCafferty
Journal:  FEMS Microbiol Lett       Date:  2010-07-02       Impact factor: 2.742

8.  Gastrointestinal tract colonization with vancomycin-resistant Enterococcus faecium in an animal model.

Authors:  M S Whitman; P G Pitsakis; E DeJesus; A J Osborne; M E Levison; C C Johnson
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

Review 9.  Clostridium difficile infection: a common clinical problem for the general internist.

Authors:  G M Caputo; M R Weitekamp; A E Bacon; C Whitener
Journal:  J Gen Intern Med       Date:  1994-09       Impact factor: 5.128

10.  In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.

Authors:  D M Citron; C V Merriam; K L Tyrrell; Y A Warren; H Fernandez; E J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.